Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | FOS | P01100 | 1/20 | 0.62 |
| ▸ | JUN | P05412 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11776532 | 0.84 | MAOB (0.58) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL11776540 | 0.84 | MAOB (0.58) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL29822711 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580362 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580365 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL20325071 | 0.82 | KDM4E (0.48) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL5323645 | 0.82 | MAOB (0.68) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL80786 | 0.82 | FOS (0.72) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL2632249 | 0.82 | MAOB (0.68) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL80787 | 0.82 | FOS (0.72) | MAOBFOSJUNBCHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9704997-B2 | Photopatternable materials and related electronic devices and methods | FLEXTERRA, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | MAOB 434/4885FOS 1860/4885JUN 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.